Alteplase recombinant
Products billed under this code include Activase, Cathflo Activase.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Activase, Cathflo Activase.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Activase | Genentech, Inc. | 50242-0044-13 | 50 | $4,920.80 |
| Activase | Genentech, Inc. | 50242-0085-27 | 100 | $9,841.60 |
| Cathflo Activase | Genentech, Inc. | 50242-0041-10 | 20 | $1,968.32 |
| Cathflo Activase | Genentech, Inc. | 50242-0041-64 | 2 | $196.832 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $98.416 | −$0.171 | 1 MG | Alteplase recombinant | v1, posted September 17, 2026 |
| 3Q26 | $98.587 | +$3.497 | 1 MG | Alteplase recombinant | v1, posted September 15, 2026 |
| 2Q26 | $95.09 | +$1.258 | 1 MG | Alteplase recombinant | v1, posted September 15, 2026 |
| 1Q26 | $93.832 | −$0.615 | 1 MG | Alteplase recombinant | v1, posted September 15, 2026 |
| 4Q25 | $94.447 | +$0.295 | 1 MG | Alteplase recombinant | v1, posted September 8, 2026 |
| 3Q25 | $94.152 | +$2.69 | 1 MG | Alteplase recombinant | v1, posted March 10, 2026 |
| 2Q25 | $91.462 | −$0.019 | 1 MG | Alteplase recombinant | v1, posted March 10, 2026 |
| 1Q25 | $91.481 | +$0.011 | 1 MG | Alteplase recombinant | v1, posted December 19, 2025 |
| 4Q24 | $91.47 | +$0.129 | 1 MG | Alteplase recombinant | v1, posted June 11, 2025 |
| 3Q24 | $91.341 | +$2.519 | 1 MG | Alteplase recombinant | v1, posted June 11, 2025 |
| 2Q24 | $88.822 | −$0.152 | 1 MG | Alteplase recombinant | v1, posted March 11, 2025 |
| 1Q24 | $88.974 | −$0.187 | 1 MG | Alteplase recombinant | v1, posted December 19, 2024 |
| 4Q23 | $89.161 | +$0.015 | 1 MG | Alteplase recombinant | v1, posted October 10, 2024 |
| 3Q23 | $89.146 | +$1.581 | 1 MG | Alteplase recombinant | v1, posted June 5, 2024 |
| 2Q23 | $87.565 | −$0.469 | 1 MG | Alteplase recombinant | v1, posted February 23, 2024 |
| 1Q23 | $88.034 | +$0.003 | 1 MG | Alteplase recombinant | v1, posted December 6, 2023 |
| 4Q22 | $88.031 | +$2.208 | 1 MG | Alteplase recombinant | v1, posted June 22, 2023 |
| 3Q22 | $85.823 | −$2.458 | 1 MG | Alteplase recombinant | v1, posted June 9, 2023 |
| 2Q22 | $88.281 | +$0.611 | 1 MG | Alteplase recombinant | v1, posted December 14, 2022 |
| 1Q22 | $87.67 | −$0.08 | 1 MG | Alteplase recombinant | v1, posted June 8, 2022 |
| 4Q21 | $87.75 | +$0.338 | 1 MG | Alteplase recombinant | v1, posted June 2, 2022 |
| 3Q21 | $87.412 | −$0.263 | 1 MG | Alteplase recombinant | v1, posted June 2, 2022 |
| 2Q21 | $87.675 | +$0.243 | 1 MG | Alteplase recombinant | v1, posted March 1, 2022 |
| 1Q21 | $87.432 | – | 1 MG | Alteplase recombinant | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.